


[도1]


IL-1β
IL-6
IL-12
TNF-α
상대적 발현수준 (Fold change)
Normal, Vehicle 대조군
ELA 0.2 U/head, Vehicle 대조군
ELA 0.2 U/head, Roflumilast 10 mg/kg, QD
ELA 0.2 U/head, 삼중 활성체의 지속형 결합체 6.5 nmol/kg, Q2D


[도2]


Normal, Vehicle
ELA, Vehicle
Roflumilast
삼중결합체
평균선형절편(mean linear intercept)
(% vs. normal)
250
200
150
100
50
**
*
Normal, Vehicle 대조군
ELA 0.2 U/head, Vehicle 대조군
ELA 0.2 U/head, Roflumilast 10 mg/kg, QD
ELA 0.2 U/head, 삼중 활성체의 지속형 결합체 6.5 nmol/kg, Q2D


[도3]



α-SMA
Col1α1
Fibronectin
상대적 발현수준 (fold increase)
p=0.056
Vehicle 대조군 (negative control)
TGF-β1 10 ng/mL only 처리군
TGF-β1 10 ng/mL + 삼중 활성체 지속형 결합체 10 μM

[도4]


Col1α1
Col3α1
상대적 발현수준 (fold increase)
Vehicle 대조군 (negative control)
TGF-β1 5 ng/mL + LPS 0.1 μg/mL 처리군
삼중 활성체 지속형 결합체 10μM + TGF-β1 5 ng/mL + LPS 0.1 μg/mL 처리군

[도5]





Normal, Vehicle 대조군


BLM 1.5 U/kg, Vehicle 대조군

BLM 1.5 U/kg, 삼중 활성체의 지속형 결합체 2.6 nmol/kg, Q2D

BLM 1.5 U/kg, Pirfenidone 300 mg/kg, QD

BLM 1.5 U/kg, Ambroxol 45 mg/kg, QD

[도6]


120
100
80
60
40
20
0
Survival rate (%)
0
3
6
7
9
12
15
18
21
Time (days after BLM treatment)
Normal, Vehicle 대조군
BLM 3.0 U/kg, Vehicle 대조군
BLM 3.0 U/kg, 삼중 활성체의 지속형 결합체 2.6 nmol/kg, Q2D
BLM 3.0 U/kg, Pirfenidone 300 mg/kg, QD
BLM 3.0 U/kg, Ambroxol 45 mg/kg, QD